+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
E

Actively Recruiting

The trial investigates how well AZD6234 works and its safety in adults who have Type 2 Diabetes Mellitus along with obesity or excess weight. This Phase III, global, randomized, double-blind study compares AZD6234 to a placebo to measure changes in body weight over 68 weeks of treatment. The study aims to better understand weight loss effects and related health changes in this population. Participants will be randomly assigned to one of three groups two different doses of AZD6234 or a placebo. The treatments are given by weekly subcutaneous injections. The study will last 68 weeks, during which participants receive their assigned injections and are monitored regularly for effectiveness and safety. Throughout the study, participants will attend multiple visits for evaluations, including body weight, waist circumference, blood pressure, and lab tests such as haemoglobin A1C and triglycerides. Some may undergo DXA scans to measure fat mass. Researchers will track changes from baseline to assess weight loss and metabolic effects. Safety and tolerability will also be monitored over the treatment period, which lasts about 68 weeks.

Age: 18Years +All GendersPhase 3
230 locations
E

Actively Recruiting

Seasonal influenza affects about one billion people worldwide each year, with 3 to 5 million cases being severe and causing up to 650,000 deaths annually. Vaccine effectiveness varies widely, often below 50%, and can be as low as 5% in people with weakened immune systems. This study aims to evaluate whether MK-1406 CD388 can help prevent influenza in adolescents and adults who are at increased risk of serious illness due to age, health conditions, or immune system weakness. Participants will receive a single dose of MK-1406 or a placebo through three subcutaneous injections during one study visit. The study is a Phase 3, randomized, double-blind, placebo-controlled trial conducted at multiple centers. It compares the safety, tolerability, and effectiveness of MK-1406 against placebo for preventing influenza in higher-risk individuals. During the study, participants will be monitored for up to approximately 24 weeks to track the occurrence of influenza-like illness, adverse events, and other health outcomes. Blood samples will be collected at specific times to measure drug levels and immune responses. Safety will be closely followed, including monitoring for injection site reactions and treatment-related antibodies. Participants health will be observed throughout the study period ending around 24 weeks post-dose.

Age: 12Years +All GendersPhase 3
185 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as a treatment for adults aged 40 to 80 years with moderate to severe chronic obstructive pulmonary disease COPD characterized by type 2 inflammation and frequent exacerbations. This Phase 3 trial aims to assess the efficacy and safety of depemokimab when added to standard care compared to a placebo with standard care. The study is sponsored by GlaxoSmithKline and focuses on reducing the rate of moderate to severe COPD exacerbations. Participants will receive either subcutaneous injections of depemokimab or placebo alongside their optimized inhaler therapies, which include inhaled corticosteroids, long-acting muscarinic antagonists, and long-acting beta2-adrenergic agonists, all maintained for at least six months prior to the study. The study uses a randomized, double-blind, parallel-group design and lasts for up to 104 weeks, during which participants continue their standard care while receiving the study treatments. Throughout the study, participants will be regularly monitored for COPD exacerbations and changes in respiratory symptoms using validated tools like the St. Georges Respiratory Questionnaire and the Evaluating Respiratory Symptoms in COPD score. Researchers will also track emergency visits or hospitalizations related to exacerbations. Safety assessments and efficacy measurements will be collected throughout the two-year period to evaluate the impact of depemokimab as an add-on treatment.

Age: 40Years - 80YearsAll GendersPhase 3
193 locations
S

Actively Recruiting

Healthy Volunteer

Researchers are studying the safety of two different doses of a Chlamydia mRNA vaccine candidate in adults. The study includes participants aged 18 to 29 years who do not have prior exposure to Chlamydia trachomatis, and those aged 18 to 44 years who are seropositive. The study aims to assess safety and possibly detect early immune responses to the vaccine. Participants are divided into two groups receiving either the first or second dose of the vaccine, or a placebo, given as three intramuscular injections. There are separate cohorts based on Chlamydia trachomatis serostatus. The study lasts about 18 months for each participant, including a 12-month follow-up after the last injection. During the study, participants will be monitored for immediate reactions after injections, injection site and systemic symptoms in the days following, and any adverse events for up to a year after vaccination. Laboratory tests will also be performed to check for abnormal results. Researchers will assess all serious adverse events throughout the study to evaluate safety comprehensively.

Age: 18Years - 44YearsAll GendersPhase 1
7 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are conducting a Phase 2b study to evaluate the safety, immune response, and effectiveness of a new bivalent protein vaccine against Respiratory Syncytial Virus RSV and Human Metapneumovirus HMPV in adults aged 60 years and older. This randomized, placebo-controlled, observer-blind trial aims to prevent lower respiratory tract diseases caused by these viruses in an elderly population. The study is sponsored by Sanofi and focuses on vaccine prevention in healthy volunteers. Participants will receive a single intramuscular injection of either the bivalent RSVHMPV protein vaccine or a matching placebo. The study includes an initial Safety Lead-in Cohort of 200 participants randomized 11 to vaccine or placebo, followed by a Main Cohort of 7,800 participants also randomized 11 after safety review. Both groups receive only one dose and are monitored over time to assess vaccine effects and safety. Throughout the study, participants will be monitored for respiratory infections caused by RSV and HMPV from 14 days up to 12 months after vaccination. Researchers will also evaluate immune responses by measuring antibody levels before vaccination and at multiple time points afterward. Safety assessments include tracking adverse events immediately after vaccination and for up to one year. The total participation duration spans about 12 months, covering vaccination, follow-up visits, and safety monitoring.

Age: 60Years +All GendersPhase 2
21 locations
E

Actively Recruiting

Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.

Age: 40Years +All GendersPhase 3
977 locations
E

Actively Recruiting

Researchers are evaluating WIN378, an ultra-long-acting medicine, in adults with moderate to severe asthma to assess its safety, how the body processes it, and its effects on lung function and asthma control. This global Phase 2 study has two parts Part A focuses on finding the right dose of WIN378, while Part B tests the chosen doses against placebo in adults with severe uncontrolled asthma to evaluate reduction in asthma flare-ups and improvements in quality of life. Participants receive WIN378 or placebo via subcutaneous injections. Part A tests three doses to understand pharmacokinetics, safety, and efficacy, including markers of inflammation in breath and blood, lung function, and asthma control. An interim analysis selects two doses for Part B, which compares these doses against placebo over 24 weeks to assess the annualized asthma exacerbation rate, lung function improvements, asthma control, and safety. During the study, participants undergo regular assessments including lung function tests, blood and breath tests for inflammation, questionnaires on asthma symptoms and quality of life, and monitoring for adverse events. Researchers track drug levels in the body and immune responses over about 60 weeks in Part A and 24 weeks after last dose in Part B. The total participation duration extends up to nearly five years, with continuous safety and efficacy monitoring.

Age: 18Years - 75YearsAll GendersPhase 2
73 locations